Clinical Trial Update: Adjunctive Selective Estrogen Receptor Modulators on Negative and Cognitive Symptoms of Schizophrenia in Women [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating adjunctive selective estrogen receptor modulators for negative and cognitive symptoms in women with schizophrenia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Snippet

Sponsor: Shanghai Mental Health Center | Conditions: Schizophrenia | Phase 4 | Status: COMPLETED